Corcept Therapeutics

Prevalence of Hypercortisolism in Individuals With Resistant Hypertension and Cardiovascular Disease

Taub et al. • 2026 • ASPC The post Prevalence of Hypercortisolism in Individuals With Resistant Hypertension and Cardiovascular Disease appeared first on Corcept Therapeutics .

Prevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension Stratified by Kidney Function: Results From the MOMENTUM Study

DeFronzo et al. • 2026 • Heart in Diabetes The post Prevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension Stratified by Kidney Function: Results From the MOMENTUM Study appeared first on Corcept Therapeutics .

Efficacy and Safety of Relacorilant + Nab-paclitaxel in Patients Aged ≥65 Years With Platinum-resistant Ovarian Cancer (PROC) in the Phase 3 ROSELLA Study (GOG-3073, ENGOT-OV72, APGOT-Ov10)

Lorusso et al. • 2026 • ESMO Gyn The post Efficacy and Safety of Relacorilant + Nab-paclitaxel in Patients Aged ≥65 Years With Platinum-resistant Ovarian Cancer (PROC) in the Phase 3 ROSELLA Study (GOG-3073, ENGOT-OV72, APGOT-Ov10) appeared first on Corcept Therapeutics .

Real-World Comparative Effectiveness of Nab-paclitaxel and Standard of Care Chemotherapies in Patients With Platinum-Resistant Ovarian Cancer (COMPASS 2.0)

Shahin et al. • 2026 • ESMO Gyn The post Real-World Comparative Effectiveness of Nab-paclitaxel and Standard of Care Chemotherapies in Patients With Platinum-Resistant Ovarian Cancer (COMPASS 2.0) appeared first on Corcept Therapeutics .

Endogenous Hypercortisolism in Individuals With Resistant Hypertension and Difficult-to-Control Type 2 Diabetes: Results From Two Large, Prospective Studies

DeFronzo et al. • 2026 • ENDO The post Endogenous Hypercortisolism in Individuals With Resistant Hypertension and Difficult-to-Control Type 2 Diabetes: Results From Two Large, Prospective Studies appeared first on Corcept Therapeutics .

Characterization of Individuals With Resistant Hypertension and Post-Dexamethasone Suppression Test Cortisol 1.8 μg/dL: Results From the MOMENTUM Study

Eilerman et al. • 2026 • ENDO The post Characterization of Individuals With Resistant Hypertension and Post-Dexamethasone Suppression Test Cortisol <1.2, 1.2–1.8, and >1.8 μg/dL: Results From the MOMENTUM Study appeared first on Corcept Therapeutics .